RxDoctor Payments Data

Shamarukh Kabir, PA

Physician Assistant · Houston, TXNPI 1851826077

Payments from drug & device makers

$8,034in general payments, 2019–2025

Across 403 payments — averaging $19.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$1K
  • AbbVie$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$849
  • Johnson & Johnson$667
  • Lundbeck LLC$626
  • Alkermes, Inc.$452
  • plus $3K from 17 others

What the payments were for

  • Food & beverage$7,96899%
  • Education$661%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,034 in reported general payments places this provider in the 90th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$12,051
Medicare patients
30
Services billed
138

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate11$82,896
RexultiBrexpiprazole21$33,157
TrintellixVortioxetine Hydrobromide23$23,615
Aripiprazole107$16,335
Lurasidone Hcl28$11,166
Chlorpromazine Hcl15$3,362
Quetiapine Fumarate147$2,623
Duloxetine Hcl64$2,343
Trazodone Hcl139$2,106
Divalproex Sodium45$1,847
Oxcarbazepine19$1,567
Olanzapine37$1,509
Mirtazapine57$1,216
Fluoxetine Hcl95$1,204
Hydroxyzine Hcl15$986

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$413$82,89611 claims
Otsuka America Pharmaceutical, Inc.Rexulti$1,161$33,15721 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$385$23,61523 claims
Almatica Pharma LLCSertraline Hcl$14$74557 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →